OKYO Pharma Ltd Files New Investor Presentation
Ticker: OKYO · Form: 6-K · Filed: Jul 10, 2024 · CIK: 1849296
Sentiment: neutral
Topics: investor-relations, filing-update
TL;DR
OKYO Pharma dropped a new investor deck on 7/10/24.
AI Summary
On July 10, 2024, OKYO Pharma Ltd announced the filing of a new investor presentation. This presentation is furnished as Exhibit 99.1 to their Form 6-K filing with the SEC.
Why It Matters
This filing provides investors with updated information and insights into OKYO Pharma's current status and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of an investor presentation, not indicating any significant new risks.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- July 10, 2024 (date) — Date of announcement
- Exhibit 99.1 (document) — Attached investor presentation
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to announce and furnish a new investor presentation as Exhibit 99.1.
When was this announcement made by OKYO Pharma Ltd?
The announcement was made on July 10, 2024.
What is the exact name of the company filing this report?
The exact name of the registrant is OKYO Pharma LTD.
Where is OKYO Pharma Ltd's principal executive office located?
OKYO Pharma Ltd's principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Is OKYO Pharma Ltd filing its annual report on Form 20-F or 40-F?
OKYO Pharma Ltd is filing its annual report on Form 20-F.
Filing Stats: 323 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-07-10 06:50:29
Filing Documents
- form6-k.htm (6-K) — 22KB
- ex99-1.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 449KB
- ex99-1_002.jpg (GRAPHIC) — 700KB
- ex99-1_003.jpg (GRAPHIC) — 141KB
- ex99-1_004.jpg (GRAPHIC) — 252KB
- ex99-1_005.jpg (GRAPHIC) — 353KB
- ex99-1_006.jpg (GRAPHIC) — 254KB
- ex99-1_007.jpg (GRAPHIC) — 349KB
- ex99-1_008.jpg (GRAPHIC) — 184KB
- ex99-1_009.jpg (GRAPHIC) — 281KB
- ex99-1_010.jpg (GRAPHIC) — 266KB
- ex99-1_011.jpg (GRAPHIC) — 171KB
- ex99-1_012.jpg (GRAPHIC) — 216KB
- ex99-1_013.jpg (GRAPHIC) — 232KB
- ex99-1_014.jpg (GRAPHIC) — 328KB
- ex99-1_015.jpg (GRAPHIC) — 229KB
- ex99-1_016.jpg (GRAPHIC) — 280KB
- ex99-1_017.jpg (GRAPHIC) — 132KB
- ex99-1_018.jpg (GRAPHIC) — 268KB
- ex99-1_019.jpg (GRAPHIC) — 251KB
- ex99-1_020.jpg (GRAPHIC) — 286KB
- ex99-1_021.jpg (GRAPHIC) — 263KB
- ex99-1_022.jpg (GRAPHIC) — 260KB
- ex99-1_023.jpg (GRAPHIC) — 292KB
- ex99-1_024.jpg (GRAPHIC) — 228KB
- ex99-1_025.jpg (GRAPHIC) — 226KB
- ex99-1_026.jpg (GRAPHIC) — 235KB
- ex99-1_027.jpg (GRAPHIC) — 280KB
- ex99-1_028.jpg (GRAPHIC) — 265KB
- ex99-1_029.jpg (GRAPHIC) — 180KB
- ex99-1_030.jpg (GRAPHIC) — 129KB
- ex99-1_031.jpg (GRAPHIC) — 225KB
- ex99-1_032.jpg (GRAPHIC) — 221KB
- ex99-1_033.jpg (GRAPHIC) — 164KB
- ex99-1_034.jpg (GRAPHIC) — 389KB
- ex99-1_035.jpg (GRAPHIC) — 268KB
- ex99-1_036.jpg (GRAPHIC) — 498KB
- 0001493152-24-026721.txt ( ) — 13480KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: July 10, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 Investor Presentation, dated July 10, 2024 4